Navigation Links
Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
Date:12/11/2008

to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(iv) In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(v) Data support that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control. (vi, vii)

About BYETTA(R) (exenatide) injection

BYETTA is the first and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA is an add-on therapy for people currently using metformin, a sulfonylurea, or a thiazolidinedione. BYETTA provides sustained A1C control, low incidence of hypoglycemia when used with metformin or a thiazolidinedione, and progressive weight loss. BYETTA was approved in April 2005 and has been used by approximately one million patients since its introduction. For full prescribing information, visit www.BYETTA.com.

Important Safety Information for BYETTA

BYETTA improves glucose (blood sugar) control in adults with type 2 diabetes. It is used with metformin, a sulfonylurea, or a thiazolidinedione. BYETTA is not a substitute for insulin in patients whose diabetes requires insulin treatment. BYETTA is not recommended for use in patients with severe problems digesting food or those who have severe disease of the stomach or kidney.

When BYETTA is used wit
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
2. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
3. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
4. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
5. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
6. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
7. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
8. Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans
9. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
10. IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)...  Cepheid (NASDAQ: CPHD ) today announced that ... invited investors to participate via webcast. ... NY Wednesday, August 13, 2014 at 9.10 a.m. ... New York, NY Thursday, September 4, 2014 ... Webcasts To access the live webcasts for these events, please ...
(Date:7/31/2014)...   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... announced that the Company will release results for the ... before the opening of the U.S. financial markets. The ... at 8:30 a.m. ET to discuss results and highlights ... to be used during the call will be available ...
(Date:7/31/2014)... 2014  Decision Resources Group,s experts are ... the Affordable Care Act (ACA), which has ... therapies. The ACA altered how Managed Care ... and expanded access via government-supported programs. Dynamic ... marketplaces set up by states or the ...
Breaking Medicine Technology:Cepheid to Webcast Upcoming Financial Presentations 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4
... Neuralstem, Inc. (NYSE Alternext US: CUR) announced today ... ALS is on clinical hold and that the ... with specific comments, questions and recommendations for modifications ... has presented us with their review of our ...
... Calif., Feb. 20 /PRNewswire-FirstCall/ -- Pharmacyclics (Nasdaq: ... a financing in connection with an investment by the ... San Bruno California and Taizhou, Jiangsu Province, People,s Republic ... $1.4 million dollar private investment into Pharmacyclics at $0.93/share. ...
Cached Medicine Technology:Neuralstem's ALS Trial on Clinical Hold 2Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd. 2Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd. 3
(Date:8/1/2014)... “When insulation goes bad,” Clean Crawls says, “It ... newly released article entitled, “ 5 Signs That Your ... ,” Clean Crawls explains the need to replace insulation ... critters. , Get a free attic insulation or ... http://www.cleancrawl.com/contact . , If crawl space or attic insulation ...
(Date:8/1/2014)... 2014 Over 20,000 entrepreneurs from around ... 2014 Market America | SHOP.COM International Convention at the ... annual event will introduce new products, technology, programs and ... and also feature a who’s who of celebrities. ... SHOP.COM Executive Team, successful entrepreneurs and celebrity guests. Previous ...
(Date:8/1/2014)... CA (PRWEB) August 01, 2014 ... advancing gynecologic endoscopic surgery, is pleased to announce ... in the United States and Europe, which strongly ... available to surgeons an endoscopic dry lab for ... of their endoscopic surgery skills. , Endoscopy is ...
(Date:8/1/2014)... 01, 2014 Stress management can be difficult ... hours of concentration and diminish rest and leisure time, stress ... is critical to find a way to manage stress in ... life. , “Having a good sense of work-life balance is ... Jacobs, founding clinician of SF Custom Chiropractic. “Stress, left ...
(Date:7/31/2014)... July 31, 2014 The 2013 ... developments about chemical listings, appellate decisions, litigation and ... may affect compliance with California's Proposition 65. , ... the law, regulations, history and trends impacting California's ... fourth installment of the series which adds approximately ...
Breaking Medicine News(10 mins):Health News:5 Signs That Insulation Should Be Replaced Detailed in a Newly Released Article By Clean Crawls 2Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 2Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 3Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 4Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 5Health News:AAGL Announces It Has Joined With Other Medical Societies to Encourage Hospitals Teaching Endoscopic Surgery to Establish Simulator Labs for Training 2Health News:SF Custom Chiropractic Celebrates National Relaxation Day and the Benefits of Massage Therapy for the Month of August 2Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2
... marketing is a missed opportunity for states to improve ... alcohol advertising laws from the Center on Alcohol Marketing ... of Public Health. The report examines the ... different best practices to reduce youth exposure to alcohol ...
... of an important clinical trial on age-related macular degeneration ... (or CATT), were published in the journal Ophthalmology ... Avastin (bevacizumab) and Lucentis (ranibizumab), commonly used to treat ... maintaining vision. In this clinical trial ...
... -- A management plan to gather, assess and respond to ... approved until they are no longer on the market is ... an Institute of Medicine report released Tuesday. The U.S. ... trial evidence that their benefits outweigh their risks. However, the ...
... MONDAY, April 30 (HealthDay News) -- A new analysis ... says those with a family history of breast cancer or ... The benefits of getting a mammogram every two years ... increased risk for developing breast cancer, according to the U.S. ...
... 1 (HealthDay News) -- Taser guns used by law enforcement ... according to a new study. Tasers, which are widely ... countries, are designed to stun suspects by delivering a 50,000-volt ... analyzed the cases of eight healthy men, ages 16 to ...
... for ordering chest CT examinations translates into positive examinations ... The study, conducted at Massachusetts General Hospital in Boston, ... of a decision support system, found that 76% of ... , "Rising concerns about radiation risks, imaging growth and ...
Cached Medicine News:Health News:Majority of states fail to address youth exposure to alcohol marketing 2Health News:Interpreting the Avastin-Lucentis study for persons with macular degeneration 2Health News:Interpreting the Avastin-Lucentis study for persons with macular degeneration 3Health News:Better Ways Needed to Track Drug Safety: Report 2Health News:Better Ways Needed to Track Drug Safety: Report 3Health News:Here Are the Women Who Need Mammograms in Their 40s: Study 2Health News:Here Are the Women Who Need Mammograms in Their 40s: Study 3
Smartepil II is a laser particularly indicated for hair-removal where it has proved to be a valid instrument, even in the treatment of darker phototypes and telangiectasias of the face and legs....
... Tri-Active is the result of ... the combination of three different methods ... to your skin. This treatment is ... of cellulite through the combined action ...
... is a CO2 laser system with ... Its functions in continuous and super-pulsed ... extreme laser intervention delicacy. Excellent as ... it comes with a large LCD ...
... professional digital imaging system for ophthalmology and ... to acquire, analyze, and store your patient ... use the most are,available right on the ... easily. This high-resolution system supports images captured ...
Medicine Products: